Subscribe
Be the first with the news that moves the market- Psychedelics stock MindBio Therapeutics receives ethics approval for its Phase 2a take-home LSD microdosing clinical trial
- The trial centers on major depressive disorder (MDD) and will test 20 patients for tolerability and feasibility of an 8 week regimen of LSD microdosing
- Despite MDD being the leading cause of global disability with over 260 million people affected, current treatments are often unreliable or altogether ineffective
- MindBio is a biotech and biopharma company focused on creating treatments for mental health conditions
- MindBio Therapeutics (CSE:MBIO) last traded at $0.115 per share
Psychedelics stock MindBio Therapeutics receives ethics approval for its Phase 2a take-home LSD microdosing clinical trial.
The trial centers on patients with major depressive disorder (MDD), has been approved by the Clinical Trials Registry, and represents the world’s first trial of its kind.
The trial involves 20 patients with MDD and will test the tolerability and feasibility of an 8 week regimen of LSD microdosing. The results will inform a Phase 2b randomized triple-dummy active placebo controlled trial.
MDD is the leading cause of global disability with over 260 million people affected. Current medical therapies are limited by slow onset and variable tolerability, with partial or total lack of efficacy in approximately one third of patients.
MindBio’s Phase 1 take-home LSD microdosing clinical trial (2022) in 80 healthy participants yielded increases in happiness, social connectivity, creativity, wellness and energy.
“Psychedelic microdosing proposes to be a globally scalable solution to treating mental health conditions and we are excited by the data we are seeing and the potential future commercialization opportunities for these medicines,” stated Justin Hanka, MindBio’s CEO.
MindBio is a biotech and biopharma company focused on creating treatments for mental health conditions. It is the first psychedelics stock in history to have clinical trials approved for LSD take-home use.
MindBio Therapeutics (CSE:MBIO) last traded at $0.115 per share.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
